Credit Suisse Ag An2 Therapeutics, Inc. Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
A detailed history of Credit Suisse Ag transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 26,630 shares of ANTX stock, worth $29,293. This represents 0.0% of its overall portfolio holdings.
Number of Shares
26,630Holding current value
$29,293% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding ANTX
# of Institutions
34Shares Held
13.7MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN5.75MShares$6.32 Million4.93% of portfolio
-
Ra Capital Management, L.P. Boston, MA2MShares$2.2 Million0.03% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.56MShares$1.71 Million0.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.04MShares$1.15 Million0.0% of portfolio
-
Peapod Lane Capital LLC Bedford Hills, NY579KShares$636,7070.79% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $21.3M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...